Technology
Health
Biotechnology

Trevena

$0.919
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0569 (-5.99%) Today
+$0.0259 (2.90%) As of 7:40 PM EDT after-hours

Why Robinhood?

You can buy or sell Trevena and other stocks, options, ETFs, and crypto commission-free!

About TRVN

Trevena, Inc. Common Stock, also called Trevena, is a biopharmaceutical company, which focuses on the development and commercialization of innovative treatment options that target and treat diseases affecting the central nervous system, or CNS. Read More The company product pipeline consists of Olinvo, TRV250, and TRV734. Trevena was founded by Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

CEO
Employees
29
Headquarters
Chesterbrook, Pennsylvania
Founded
2007
Market Cap
87.74M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
506.25K
High Today
$0.9979
Low Today
$0.86
Open Price
$0.96
Volume
996.54K
52 Week High
$3.58
52 Week Low
$0.3823

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
2014 IPO
US
North America

TRVN News

Yahoo FinanceJun 24

Trevena Announces Publication of APOLLO-2 Results in Pain Practice

1,500

TRVN Earnings

-$0.27
-$0.20
-$0.13
-$0.06
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, Pre-Market

Popular Stocks

More TRVN News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.